Metabolic Syndrome: Hyperlipidemia.
Metabolic syndrome is associated with an elevated risk of cardiovascular disease and premature mortality. When metabolic syndrome includes lipid abnormalities, management goals are weight loss and cardiovascular risk management through lifestyle modifications (eg, diet, exercise), and, when appropriate, lowering of lipid levels with pharmacotherapy. Healthy diets are recommended, particularly the Mediterranean diet. Patients also should set a goal of at least 30 minutes of moderate to vigorous exercise on most, preferably all, days of the week. Guidelines provide criteria for statin treatment based on overall cardiovascular risk. High-intensity statin treatment (eg, rosuvastatin 20 to 40 mg, atorvastatin 40 to 80 mg) typically is recommended unless the patient cannot tolerate therapy. Approximately 5% of patients experience statin-induced myalgia, in which case moderate-intensity treatment can be tried. Lipid levels should be reevaluated 4 to 12 weeks after initiating therapy; lipid levels can be measured without fasting. A lack of improvement often indicates nonadherence. Bile acid sequestrants, fibric acids, and niacin can be used if other drugs are not tolerated. The evidence to support use of integrative medicine is limited, but the strongest evidence of benefit is for garlic (Allium sativum).
Department of Family and Community Medicine at the University of Kansas School of Medicine-Wichita, 707 N. Emporia, Wichita, KS 67214.
Dee Ann Stults
DA
Bragg
Department of Family and Community Medicine at the University of Kansas School of Medicine-Wichita, 707 N. Emporia, Wichita, KS 67214.
Anne
A
Walling
D050197:Atherosclerosis / Q000517:prevention & control* / Q000628:therapy; D015444:Exercise; D005247:Feeding Behavior; D058607:Fibric Acids / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D015228:Hypertriglyceridemia / Q000150:complications / Q000188:drug therapy; D024821:Metabolic Syndrome / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D040242:Risk Reduction Behavior; D015431:Weight Loss
D058607:Fibric Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors